# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
GoodRx's Q1 earnings: $0.08 EPS, sales hit $197.88 million, beating expectations fueled by prescription transactions and ph...
GoodRx Holdings Inc (NASDAQ: GDRX) got an upgrade last month from Wells Fargo analyst.
Keybanc analyst Scott Schoenhaus upgrades GoodRx Holdings (NASDAQ:GDRX) from Sector Weight to Overweight and announces $9 pr...
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
Wells Fargo's upgrade of GoodRx Holdings. Analysts anticipate strong revenue visibility and EBITDA margins, setting the sta...